Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

PHASE2UnknownINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

August 31, 2018

Conditions
Cervical Intraepithelial Neoplasia
Interventions
BIOLOGICAL

GX-188E

1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.

BIOLOGICAL

Placebo

0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.

Trial Locations (16)

10119

East Tallinn Central Hospital, Tallinn

13419

North Estonia Medical Centre Foundation, Tallinn

41931

Keimyung University Dongsan Medical Center, Daegu

47392

Inje University Busan Paik Hospital, Busan

51014

Tartu University Hospital, Tartu

61070

Kharkiv medical academy of postgraduate education, Kharkiv

65026

Multi-profile Medical Center (University Clinic No. 1) of Odesa National, Odesa

69071

State Institution Zaporizhzhia Medical Academy of Post-Graduate Education, Zaporizhzhya

03722

Severance Hospital, Seoul

04619

Cheil General Hospital & Women's Healthcare Center, Seoul

06135

CHA Gangnam Medical Center, Seoul

06591

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

07441

Hallym University Kangnam Sacred Heart Hospital, Seoul

07985

Ehwa Womans University Mokdong Hospital, Seoul

080308

Korea University Guro Hospital, Seoul

04050

National Academy of Medical Sciences of Ukraine, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT02596243 - Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) | Biotech Hunter | Biotech Hunter